CROSSJECT (ALCJ.PA) Stock Fundamental Analysis

EPA:ALCJ • FR0011716265

1.93 EUR
0 (0%)
Last: Feb 18, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

Taking everything into account, ALCJ scores 1 out of 10 in our fundamental rating. ALCJ was compared to 67 industry peers in the Health Care Equipment & Supplies industry. ALCJ has a bad profitability rating. Also its financial health evaluation is rather negative. ALCJ has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ALCJ had negative earnings in the past year.
  • ALCJ had a negative operating cash flow in the past year.
  • ALCJ had negative earnings in each of the past 5 years.
  • In the past 5 years ALCJ always reported negative operating cash flow.
ALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • ALCJ has a Return On Assets of -35.89%. This is amonst the worse of the industry: ALCJ underperforms 83.58% of its industry peers.
  • ALCJ has a worse Return On Equity (-308.38%) than 88.06% of its industry peers.
Industry RankSector Rank
ROA -35.89%
ROE -308.38%
ROIC N/A
ROA(3y)-34.88%
ROA(5y)-33.65%
ROE(3y)-354.28%
ROE(5y)-361.76%
ROIC(3y)N/A
ROIC(5y)N/A
ALCJ.PA Yearly ROA, ROE, ROICALCJ.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALCJ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCJ.PA Yearly Profit, Operating, Gross MarginsALCJ.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • ALCJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALCJ has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ALCJ has more shares outstanding
  • The debt/assets ratio for ALCJ is higher compared to a year ago.
ALCJ.PA Yearly Shares OutstandingALCJ.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ALCJ.PA Yearly Total Debt VS Total AssetsALCJ.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of 0.35, we must say that ALCJ is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 0.35, ALCJ is not doing good in the industry: 70.15% of the companies in the same industry are doing better.
  • ALCJ has a Debt/Equity ratio of 2.52. This is a high value indicating a heavy dependency on external financing.
  • ALCJ's Debt to Equity ratio of 2.52 is on the low side compared to the rest of the industry. ALCJ is outperformed by 85.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF N/A
Altman-Z 0.35
ROIC/WACCN/A
WACC7.57%
ALCJ.PA Yearly LT Debt VS Equity VS FCFALCJ.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • ALCJ has a Current Ratio of 0.93. This is a bad value and indicates that ALCJ is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.93, ALCJ is not doing good in the industry: 86.57% of the companies in the same industry are doing better.
  • ALCJ has a Quick Ratio of 0.93. This is a bad value and indicates that ALCJ is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.59, ALCJ is doing worse than 86.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.59
ALCJ.PA Yearly Current Assets VS Current LiabilitesALCJ.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.80% over the past year.
  • ALCJ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)13.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.07%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 56.77% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 98.55% on average over the next years. This is a very strong growth
EPS Next Y135.12%
EPS Next 2Y83.48%
EPS Next 3Y56.77%
EPS Next 5YN/A
Revenue Next Year428.6%
Revenue Next 2Y140.35%
Revenue Next 3Y98.55%
Revenue Next 5YN/A

3.3 Evolution

ALCJ.PA Yearly Revenue VS EstimatesALCJ.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
ALCJ.PA Yearly EPS VS EstimatesALCJ.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALCJ. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 5.45, the valuation of ALCJ can be described as very cheap.
  • ALCJ's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALCJ is cheaper than 97.01% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of ALCJ to the average of the S&P500 Index (28.16), we can say ALCJ is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.45
ALCJ.PA Price Earnings VS Forward Price EarningsALCJ.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCJ.PA Per share dataALCJ.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 0.3

4.3 Compensation for Growth

  • ALCJ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ALCJ's earnings are expected to grow with 56.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y83.48%
EPS Next 3Y56.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ALCJ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CROSSJECT

EPA:ALCJ (2/18/2026, 7:00:00 PM)

1.93

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-24
Earnings (Next)03-25
Inst Owners0.2%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap100.84M
Revenue(TTM)N/A
Net Income(TTM)-11.26M
Analysts86
Price Target4.11 (112.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.14%
PT rev (3m)6.14%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-37.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)36.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.45
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 27.61
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)0.35
Fwd EY18.36%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS0.07
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.89%
ROE -308.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.88%
ROA(5y)-33.65%
ROE(3y)-354.28%
ROE(5y)-361.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.59
Altman-Z 0.35
F-Score3
WACC7.57%
ROIC/WACCN/A
Cap/Depr(3y)131.18%
Cap/Depr(5y)130.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.07%
EPS Next Y135.12%
EPS Next 2Y83.48%
EPS Next 3Y56.77%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year428.6%
Revenue Next 2Y140.35%
Revenue Next 3Y98.55%
Revenue Next 5YN/A
EBIT growth 1Y5.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year190.19%
EBIT Next 3Y71.66%
EBIT Next 5YN/A
FCF growth 1Y20.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.35%
OCF growth 3YN/A
OCF growth 5YN/A

CROSSJECT / ALCJ.PA FAQ

What is the fundamental rating for ALCJ stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA.


Can you provide the valuation status for CROSSJECT?

ChartMill assigns a valuation rating of 4 / 10 to CROSSJECT (ALCJ.PA). This can be considered as Fairly Valued.


What is the profitability of ALCJ stock?

CROSSJECT (ALCJ.PA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CROSSJECT?

The Earnings per Share (EPS) of CROSSJECT (ALCJ.PA) is expected to grow by 135.12% in the next year.